The mammalian target of rapamycin inhibitor RAD001 (everolimus) in early breast cancer
dc.contributor.author
Macaskill, Elizabeth Jane
en
dc.date.accessioned
2018-03-29T12:18:24Z
dc.date.available
2018-03-29T12:18:24Z
dc.date.issued
2010
dc.description.abstract
en
dc.description.abstract
The mammalian target of rapamycin (mTOR) plays a key role in tumour cell cycle
control, proliferation and survival, and has been implicated in resistance to endocrine
therapy in breast cancer. RAD001 (everolimus) is a novel macrolide that inhibits
mTOR and its downstream substrates in vitro. This study explores the use of
RAD001 at a dose of 5mg daily in women with early breast cancer.
31 postmenopausal women were given RAD001 for 14 days prior to primary surgical
intervention for early breast cancer. RAD001 was well tolerated in most patients, 5
did not complete treatment due to drug adverse effects.
Tumour samples before (pre) and after (post) 14 days treatment were assessed for
changes in proliferation and markers of the mTOR pathway. Significant reductions in
proliferation (Ki67) and oestrogen receptor (ER) expression were seen, and the
downstream effects of the mTOR pathway inhibited (p-S6 (ser235/236 and ser
240/244) and nuclear expression of p-Akt). Gene expression profiling from these
tumour samples has confirmed these findings, demonstrating reduction in expression
of proliferative genes and oestrogen dependence genes with RAD001 treatment.
The mTOR protein exists in two distinct complexes, raptor and rictor, and it has
previously been thought that mTOR inhibitors such as RAD001 only have effects
upon raptor. The implication of this if correct would be upregulation of Akt (Protein
Kinase B), which has been shown to be present in more aggressive and resistant
tumour types. The cell line study described herein has demonstrated no upregulation
in p-Akt expression with RAD001 treatment, and in one cell line inhibition of p-Akt
was sustained with prolonged cell treatment.
en
dc.identifier.uri
http://hdl.handle.net/1842/29235
dc.publisher
The University of Edinburgh
en
dc.relation.ispartof
Annexe Thesis Digitisation Project 2018 Block 17
en
dc.relation.isreferencedby
Already catalogued
en
dc.title
The mammalian target of rapamycin inhibitor RAD001 (everolimus) in early breast cancer
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
MD Doctor of Medicine
en
Files
Original bundle
1 - 1 of 1
- Name:
- MacaskillEJ_2010redux.pdf
- Size:
- 31.77 MB
- Format:
- Adobe Portable Document Format
This item appears in the following Collection(s)

